StockData
Genmab A/S logo

Genmab A/S

GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)

Close on Nov 18, 2026

Genmab A/S Total Merus Acquisition Borrowings by Quarter

Total Merus Acquisition Borrowings (Carrying Amount) ($M)

Genmab A/S Total Merus Acquisition Borrowings: $4,992M in Q3 2026.

Latest, Q3 2026
4,992
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
3
Documents cited below

Where the Q3 2026 figure comes from

“|| Ending Balance as of 9/30/2026 | $ | 926 | $ | 1,674 | $ | 1,439 | $ | 953 | $ | 4,992”

Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗

$5.5B debt financing package closed in December 2025 to fund the $8.0B all-cash acquisition of Merus N.V. ($0 borrowings in FY2023–FY2024; $288M principal repaid in 9M 2026).

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Breakdown

What makes up total Merus Acquisition Borrowings

Cite this data

StockData. (2026). Genmab A/S Total Merus Acquisition Borrowings ($M), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/debt-total

See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.

See a number that looks wrong?